Market open
Gilead Sciences/$GILD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Ticker
$GILD
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
17,600
Website
Gilead Sciences Metrics
BasicAdvanced
$130B
275.11
$0.38
0.34
$3.10
3.02%
Price and volume
Market cap
$130B
Beta
0.34
52-week high
$119.96
52-week low
$62.07
Average daily volume
10M
Dividend rate
$3.10
Financial strength
Current ratio
1.597
Quick ratio
1.201
Long term debt to equity
131.944
Total debt to equity
144.155
Dividend payout ratio (TTM)
816.25%
Interest coverage (TTM)
10.94%
Management effectiveness
Return on assets (TTM)
11.03%
Return on equity (TTM)
2.29%
Valuation
Price to earnings (TTM)
275.105
Price to revenue (TTM)
4.534
Price to book
6.74
Price to tangible book (TTM)
-14.45
Price to free cash flow (TTM)
12.65
Dividend yield (TTM)
2.97%
Forward dividend yield
3.02%
Growth
Revenue change (TTM)
6.04%
Earnings per share change (TTM)
-91.56%
3-year revenue growth (CAGR)
1.74%
3-year earnings per share growth (CAGR)
-57.44%
3-year dividend per share growth (CAGR)
2.74%
What the Analysts think about Gilead Sciences
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Gilead Sciences stock.
Gilead Sciences Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Gilead Sciences Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Gilead Sciences News
AllArticlesVideos
Gilead says Trodelvy-Keytruda combo effective for aggressive breast cancer type
Reuters·2 hours ago
Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer
Business Wire·2 hours ago
Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Gilead Sciences stock?
Gilead Sciences (GILD) has a market cap of $130B as of April 21, 2025.
What is the P/E ratio for Gilead Sciences stock?
The price to earnings (P/E) ratio for Gilead Sciences (GILD) stock is 275.11 as of April 21, 2025.
Does Gilead Sciences stock pay dividends?
Yes, the Gilead Sciences (GILD) stock pays dividends to shareholders. As of April 21, 2025, the dividend rate is $3.1 and the yield is 3.02%. Gilead Sciences has a payout ratio of 816.25% on a trailing twelve-month basis.
When is the next Gilead Sciences dividend payment date?
The next Gilead Sciences (GILD) dividend payment date is unconfirmed.
What is the beta indicator for Gilead Sciences?
Gilead Sciences (GILD) has a beta rating of 0.34. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.